In the present study, the expression of mTOR and phosphorylated mTOR (pmTOR, the active form of mTOR) was examined in stage IIIB colon cancer, and their correlation with clinicopathological characteristics was investigated, to provide prognostic value and potential molecular targets for future novel therapies. This evidence concerns the gene MTOR and malignant colon neoplasm.